Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Lillestol Research LLC

Neither a doctor nor a teaching hospital

Research payments

$19,558,496

1,192 payments

Through program year 2025, Lillestol Research LLC is reported as receiving $19,558,496 in research payments, across 1,192 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,305,508 111
2024 Research $3,195,008 112
2023 Research $2,861,642 107
2022 Research $2,428,198 157
2021 Research $3,416,407 247
2020 Research $2,772,788 179
2019 Research $1,578,945 279

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $8,943,245 156 payments
  2. Pfizer Inc. $5,467,584 467 payments
  3. Novartis Pharmaceuticals Corporation $2,098,079 17 payments
  4. Amgen Inc. $1,327,320 39 payments
  5. Moderna TX, Inc. $831,967 129 payments
  6. Sanofi US Services Inc. $220,477 80 payments
  7. Exeltis, USA Inc. $120,230 51 payments
  8. Novo Nordisk AS $111,185 17 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $84,507 7 payments
  10. Esperion Therapeutics, Inc. $80,800 108 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $2,783,056 90 payments
  2. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $1,662,698 8 payments
  3. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity $1,538,641 4 payments
  4. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $873,602 198 payments
  5. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $797,019 9 payments
  6. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $723,606 90 payments
  7. A Phase 2 Study of Once-Daily Ly3502970 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $651,468 4 payments
  8. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $618,340 4 payments
  9. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $569,532 40 payments
  10. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $511,912 27 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record